Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-05-18FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone mesylate) filed by Viatris Specialty LLC.
-
FDA approval · 2021-05-18FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2021-05-13FDA Approved: LURASIDONE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approves Alembic Pharmaceuticals' generic Lurasidone hydrochloride tablets under an Original Application (ANDA213248). Lurasidone is use…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Boost rTMS for Auditory Verbal Hallucinations [NA]
Clinical trial update for rTMS in auditory verbal hallucinations associated with schizophrenia; study is terminated with results posted.
-
FDA approval · 2021-04-28FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC, resulting in an update to the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: Pan European Collaboration on Antipsychotic Naïve Schizophrenia II [Phase 4]
Phase 4 clinical trial update on antipsychotic naïve schizophrenia from a pan-European collaboration; study completed.
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia [Phase 2, Phase 3]
This clinical trial update reports results from a long-term Phase 2/3 study of MP-214 in adults with chronic-phase or elderly schizophrenia,…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia [Phase 2, Phase 3]
Long-term Phase 2/3 study of MP-214 in schizophrenia; results have been posted.
-
CLINICAL_TRIALS trial_result · 2021-04-12Clinical Trial Update: Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia [Phase 2]
This completed Phase 2 trial evaluated the safety, pharmacokinetics, and efficacy of MP-214 in adults with schizophrenia. Results have been …
-
CLINICAL_TRIALS trial_result · 2021-04-12Clinical Trial Update: A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia [Phase 2, Phase 3]
This is a completed pharmacokinetic study of MP-214 in patients with schizophrenia. Results were posted on April 12, 2021.
-
CLINICAL_TRIALS trial_result · 2021-04-12Clinical Trial Update: Safety and Efficacy of MP-214 in Patients With Schizophrenia [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating MP-214 for schizophrenia has completed and its results have been posted.
-
CLINICAL_TRIALS trial_result · 2021-04-12Clinical Trial Update: Long-Term Study of MP-214 in Patients With Schizophrenia [Phase 2, Phase 3]
This document reports the completion of a long-term Phase 2/3 trial evaluating MP-214 for schizophrenia, with results posted on 2021-04-12.
-
CLINICAL_TRIALS trial_result · 2021-04-12Clinical Trial Update: Treating Refractory Schizophrenia With rTMS [NA]
A clinical trial investigating repetitive transcranial magnetic stimulation (rTMS) for refractory schizophrenia was terminated; results were…
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers [NA]
Completed clinical trial studying motivational negative symptoms in schizophrenia with biomarkers; results posted in 2021.
-
FDA approval · 2021-03-30FDA Approved: ARISTADA — Supplemental Application (Alkermes, Inc.)
The FDA approved a supplemental application for ARISTADA (aripiprazole lauroxil) from Alkermes, Inc., to update the product labeling as requ…
-
FDA approval · 2021-03-30FDA Approved: ARISTADA INITIO — Supplemental Application (Alkermes, Inc.)
FDA approved a supplemental application for Aristada Initio (aripiprazole lauroxil) from Alkermes, adding an initiation option for schizophr…
-
CLINICAL_TRIALS trial_result · 2021-03-29Clinical Trial Update: A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) [Phase 1]
Phase 1 trial update on MK-8189 assessing safety, tolerability, and pharmacokinetics in participants with schizophrenia and healthy voluntee…
-
FDA approval · 2021-03-09FDA Approved: ASENAPINE — Original Application (Breckenridge Pharmaceutical, Inc.)
FDA approved a generic version of asenapine (asenapine maleate) from Breckenridge Pharmaceutical, Inc. via an Original Application (ANDA2059…
-
FDA approval · 2021-03-01FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved the original application for fluphenazine hydrochloride as a generic product, submitted by ANI Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Lurasidone Effects on Tissue Glutamate in Schizophrenia [Phase 4]
Phase 4 trial updates on lurasidone effects on tissue glutamate in schizophrenia and schizoaffective disorder; results posted after completi…
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study [Phase 1]
Phase 1 first-in-human safety, tolerability, and pharmacokinetics study (TAK-041) in schizophrenia and healthy volunteers completed; results…
-
CLINICAL_TRIALS trial_result · 2021-02-24Clinical Trial Update: Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating BI 425809 on cognition and functional capacity in schizophrenia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study [Phase 3]
A Phase 3 randomized, double-blind trial comparing ziprasidone to olanzapine in recent-onset psychosis (schizophrenia/psychotic disorders) c…
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients [Phase 3]
Phase 3 study comparing ziprasidone to risperidone for schizophrenia in Chinese patients has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia [Phase 3]
Phase 3 trial comparing safety and efficacy of ziprasidone versus risperidone for chronic schizophrenia was terminated.